TICKERNERD
Menu
COGTCOGTHealthcare · Biotechnology

COGT Stock Forecast: Cogent Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$37
+4.02% on the day

The 12 Wall Street analysts covering Cogent Biosciences, Inc. hold a median 12-month price target of $55 — +49.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.4B
Ticker Nerd rank
35 / 100
Median analyst target
$55
Analysts covering
12
Total return, dividends reinvested
1W
−3.2%
1M
−7.3%
YTD
+3.4%
1Y
+212.1%
From 52W high
−14.3%
From 52W low
+212.1%
$12
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COGT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cogent Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Value
70
Volatility
58
Revisions
51
Accruals
47
Quality
37
Growth
36
Size
21
Issuance
7

Momentum (91): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COGT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COGT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26COGTHigh $62Median $55Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $45Median $55High $62

The green dot is the last close — the median target sits +49.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Piper SandlerMaintainsOverweight$52 → $55
12 Aug 2026GuggenheimMaintainsBuy$45 → $52
29 May 2026WedbushReiteratesOutperform$55
29 May 2026WedbushReiteratesOutperform—
6 May 2026HC Wainwright & Co.MaintainsBuy—
17 Mar 2026WedbushReiteratesOutperform—
16 Mar 2026JefferiesAssumesBuy$55
18 Feb 2026Piper SandlerMaintainsOverweight—
21 Jan 2026WedbushReiteratesOutperform—
6 Jan 2026HC Wainwright & Co.MaintainsBuy—
19 Dec 2025JP MorganMaintainsOverweight—
8 Dec 2025NeedhamReiteratesHold—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025BairdMaintainsNeutral—
10 Nov 2025Leerink PartnersMaintainsOutperform—
4 Nov 2025HC Wainwright & Co.ReiteratesBuy—
21 Oct 2025JP MorganMaintainsOverweight—
16 Oct 2025StifelInitiatesHold—
3 Sept 2025Raymond JamesInitiatesStrong Buy—
25 Aug 2025GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COGT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

COGT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
7
Fundamentals

Cogent Biosciences, Inc. (COGT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.0×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
13.5×

Cheaper than 8% of US stocks

EV / EBITDA
−15.2×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−109.7%

Higher than 12% of US stocks

Return on assets
−43.8%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

COGT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COGTCogent Biosciences, Inc.$6.4B
35
MIRMMirum Pharmaceuticals, Inc.$6.3B
69
TVTXTravere Therapeutics, Inc.$6.2B
84
DNTHDianthus Therapeutics, Inc.$6.0B
60
ERASErasca, Inc.$6.0B
55
DFTXDefinium Therapeutics, Inc.$5.8B
40
XENEXenon Pharmaceuticals, Inc.$5.8B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cogent Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COGT news & analysis

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research noted that Cogent Biosciences (COGT) shares have formed a hammer chart pattern, suggesting the stock found support after recent declines. This technical indicator, combined with an upward trend in earnings estimate revisions, could signal a near-term trend reversal for the stock.

Why it matters — A COGT watcher would care because the technical chart pattern and improving earnings estimates may indicate the stock has stopped losing value and could be poised to move higher.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

GlobeNewsWire · 10 Aug 2026positive

Cogent Biosciences reported second-quarter 2026 financial results, highlighting that it is on track for potential FDA approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30), and has submitted an AdvSM New Drug Application to the FDA. The company also reported a pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028.

Why it matters — A COGT watcher would care because the company is approaching two major PDUFA dates later this year for bezuclastinib, which could be pivotal catalysts for the stock.

FAQ

Frequently asked questions about COGT stock

What is the COGT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Cogent Biosciences, Inc. have a median 12-month price target of $55, with estimates ranging from $45 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COGT stock a buy right now?

Of the 12 analysts covering Cogent Biosciences, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cogent Biosciences, Inc. 35 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COGT?

As at 22 Aug 2026, Cogent Biosciences, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will COGT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +49.7% from the last close, and Ticker Nerd's factor model ranks Cogent Biosciences, Inc. 35 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COGT stock forecast for 2030?

No analyst covering Cogent Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COGT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $62 over the next 12 months.

How has COGT stock performed over the past year?

Cogent Biosciences, Inc. returned +212.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cogent Biosciences, Inc. do?

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing small-molecule precision therapies for genetically defined diseases.

What is the latest news on COGT?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now". Zacks Investment Research noted that Cogent Biosciences (COGT) shares have formed a hammer chart pattern, suggesting the stock found support after recent declines. This technical indicator, combined with an upward trend in earnings estimate revisions, could signal a near-term trend reversal for the stock.

Company

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing small-molecule precision therapies for genetically defined diseases. It focuses on modulating the tumor microenvironment, particularly through inhibitors targeting colony-stimulating factor 1 receptor (CSF1R), a regulator of tumor-associated macrophages that promote tumor growth and immune evasion. The company's lead candidate, an orally bioavailable CSF1R inhibitor, is in early-stage clinical trials for solid tumors, demonstrating preclinical antitumor activity alone and combined with checkpoint inhibitors. Cogent Biosciences also advances CGT9486, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V mutations and other KIT exon 17 alterations, addressing systemic mastocytosis, gastrointestinal stromal tumors, and additional solid tumor indications. Its pipeline emphasizes immune-regulatory pathways in oncology, leveraging collaborations with academic institutions and contract research organizations. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences plays a vital role in advancing targeted immuno-oncology treatments to address unmet needs in precision medicine.

CEO Mr. Andrew R. Robbins M.B.A. · 258 employees · United States · https://www.cogentbio.com